(19) |
 |
|
(11) |
EP 1 374 899 A8 |
(12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
published in accordance with Art. 158(3) EPC |
(48) |
Corrigendum issued on: |
|
10.03.2004 Bulletin 2004/11 |
(43) |
Date of publication: |
|
02.01.2004 Bulletin 2004/01 |
(22) |
Date of filing: 15.03.2002 |
|
(86) |
International application number: |
|
PCT/JP2002/002513 |
(87) |
International publication number: |
|
WO 2002/076505 (03.10.2002 Gazette 2002/40) |
|
(84) |
Designated Contracting States: |
|
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
Designated Extension States: |
|
AL LT LV MK RO SI |
(30) |
Priority: |
16.03.2001 JP 2001075398
|
(71) |
Applicant: ONO PHARMACEUTICAL CO., LTD. |
|
Osaka-shi, Osaka 541-8526 (JP) |
|
(72) |
Inventors: |
|
- NARUMIYA, Shuh
Kyoto-shi, Kyoto 606-0007 (JP)
- MARUYAMA, Takayuki, Ono Pharmaceutical Co., Ltd.
Mishima-gun, Osaka 618-8585 (JP)
|
(74) |
Representative: Henkel, Feiler, Hänzel |
|
Möhlstrasse 37 81675 München 81675 München (DE) |
|
|
|
(54) |
REMEDIES FOR POST-TRAUMATIC STRESS DISORDER |
(57) The treatment and/or prophylactic drugs of post-traumatic stress disorder (PTSD)
containing compounds(EP
1 agonists), which activate EP
1 receptor that is subtype of prostaglandin E2 receptor, as an active ingredient. EP
1 agonists such as (13E)-(11 α, 15S, 17S)-2, 5-ethano-6, 9-dioxo-11, 15-dihydro-17,
20-dimethylprosta-13-enoic acid, PGE
1, or PGE
2, etc. are useful for the treatment of post-traumatic stress disorder (PTSD).